Joseph Monahan - 01 Jun 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Jun 2021
Net transactions value: -$471,437
Form type: 4
Filing time: 02 Jun 2021, 21:45:41 UTC
Previous filing: 17 May 2021
Next filing: 02 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+50,000	+88%		107,132	01 Jun 2021	Direct	F1
transaction	ACRS	Common Stock	Sale	$392,231	-18,240	-17%	$21.50	88,892	02 Jun 2021	Direct	F2, F3
transaction	ACRS	Common Stock	Sale	$79,205	-3,550	-4%	$22.31	85,342	02 Jun 2021	Direct	F2, F4
holding	ACRS	Common Stock						193	01 Jun 2021	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-50,000	-100%	$0.000000^*	0	01 Jun 2021	Common Stock	50,000		Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
F3	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.03 to $22.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	The shares underlying these restricted stock units vested on June 1, 2021.